METTL3 increases MALAT1 protein levels in an m6A modification-dependent manner, recruits E2F1 and activates downstream AGR2 transcription to enhance the resistance of breast cancer cells to doxorubicin [48]. The gene discussed is METTL3; the disease is breast carcinoma.